Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness

Br J Haematol. 2019 May;185(4):755-757. doi: 10.1111/bjh.15601. Epub 2018 Oct 18.
No abstract available

Keywords: ETP-ALL; T-ALL; cytarabine; leukaemia; sorafenib.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage
  • Dose-Response Relationship, Drug
  • Female
  • Granulocyte Colony-Stimulating Factor / administration & dosage
  • Humans
  • Idarubicin / administration & dosage
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Sorafenib / administration & dosage
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives

Substances

  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Sorafenib
  • Vidarabine
  • Idarubicin

Supplementary concepts

  • Ida-FLAG protocol